AstraZeneca reports at ASCO that its drug Tagrisso slowed down lung cancer progression for a median of several years in stage ...

The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago — is ...

At ASCO, Astra Zeneca reported that its drug Enhertu stalled the growth of tumors by more than a year in women with the most ...

At an ASCO 2024 event, Richard Pazdur, the FDA's top oncologist, said the agency wants to see companies conducting studies ...

Recap: Today's top stories from ASCO 2024 include updates on safety data about a myelofibrosis candidate, and record ...

At a STAT event, oncology leaders spoke of advances that are turning old ideas like antibody-drug conjugates into broadly ...

Corbus, reporting on early trials of its antibody-drug conjugate, says it "seems to be clinically effective in bladder cancer ...

The Biden administration has significantly opened the door to drug treatment strategies that help reduce substance use, even ...

The effectiveness and safety of MDMA-assisted therapy for post-traumatic stress disorder will be scrutinized soon by FDA ...

CHICAGO — People can be mightily reluctant to get a colonoscopy for reasons like cost, language barriers, or fear of what the ...

One data point makes new results on Pfizer's cancer drug Lorbrena quite eye-catching: It reduced disease progression by 81%.

While many sickle cell patients have felt pressure to end a pregnancy, others are pressured to keep a pregnancy.